Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution

The Lancet Respiratory Medicine

Volumn 4, Issue 9, 2016, Pages e46-e47

  Raghu, Ganesh ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; STOMACH SECRETION INHIBITOR;

COMMUNITY ACQUIRED PNEUMONIA; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; INFECTION; LETTER; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

EID: 84989916014     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30234-X     Document Type: Letter

References (10)

1. 1 Kreuter, M, Wuyts, W, Renzoni, E, et al. Anti-acid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 4 (2016), 381–389.
2. 2 Lee, JS, Collard, HR, Anstrom, KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 1 (2013), 369–376.
3. 3 Raghu, G, Freudenberger, TD, Yang, S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 27 (2006), 136–142.
4. 4 Johnson, WC, Raghu, G, Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures. Eur Respir J 26 (2005), 755–758.
5. 5 King, TE Jr, Albera, C, Bradford, WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (inspire): A multicentre, randomised, placebo-controlled trial. Lancet 374 (2009), 222–228.
6. 6 King, TE Jr, Brown, KK, Raghu, G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184 (2011), 92–99.
7. 7 Filion, KB, Chateau, D, Targownik, LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 63 (2014), 552–558.
8. 8 Nathan, SD, Anti-acid therapy and idiopathic pulmonary fibrosis: cause for heartburn?. Lancet Respir Med 4 (2016), 340–341.
9. 9 Raghu, G, Rochwerg, B, Zhang, Y, et al. An official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192 (2015), e3–19.
10. 10 Rochwerg, B, Schünemann, HJ, Raghu, G, Idiopathic pulmonary fibrosis—clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?. BMC Med, 14, 2016, 22.